INSTRUCTIONS TO AUTHORS

Molecular Pharmacology will publish the results of investigations that contribute significant new information on drug action or selective toxicity at the molecular level. The term "drug" is defined broadly to include chemicals that selectively modify biological function.

Suitable papers are those that describe applications of the methods of biochemistry, biophysics, genetics, and molecular biology to problems in pharmacology or toxicology. Also suitable are reports of fundamental investigations which, although not concerned directly with drugs, nevertheless provide an immediate basis for further study of the molecular mechanism of drug action. Observations of phenomena that shed no light upon underlying molecular interactions are not appropriate for publication. Comparative studies, such as those involving drug-receptor or drug-enzyme interactions that already have been well characterized in other types of cells or tissues, also are inappropriate for publication unless they contribute significant new insight into mechanisms.

Molecular Pharmacology has adopted a uniform policy for evaluation of manuscripts utilizing molecular modeling. Key aspects of content that determine suitability and eventual acceptance include: use of modeling technology to generate predictions concerning new molecules, modeling studies that offer significant new insights into the mechanism of actions of drugs, and inclusion of experimental data that support the predictions of molecular modeling. It is not necessary that each aspect be reflected in every manuscript; however, manuscripts that are purely theoretical in nature or that simply generate structural predictions without correlating these to drug action or new biological data will be returned as unsuitable for publication.

Specific areas of interest include: identification and characterization of receptors for hormones, growth factors, neurotransmitters, toxins, and other drugs; analysis of receptor response pathways; drug effects on metabolic pathways, biosynthesis and degradation of macromolecules, and cellular regulatory mechanisms; analysis of drug-receptor and drug-enzyme interactions; effects of drugs on structure and properties of macromolecules and membranes; relationships between drug structure and activity; molecular mechanisms of drug metabolism; distribution and transport between biological compartments; molecular mechanisms of chemical mutagenesis, carcinogenesis, and teratogenesis; and molecular mechanisms of selective toxicity, drug allergy, and pharmacogenetics.

Page charges. Authors will be billed at the rate of $40.00 per page after the paper has been published. It is expected that the page charge will be paid if funds are available for that purpose from the author's institution or from the sponsor of this research. Payment of the charge is not a condition for publication. In case of personal financial hardship, page charges will be waived. Neither the editors nor the reviewers will have knowledge as to who has paid the charge, and this payment always will be considered entirely voluntary.

Submission of manuscript. Manuscripts are published in English only and should be sent to **Dr. T. Kendall Harden, Editor, *Molecular Pharmacology*, CB 7368, Department of Pharmacology, University of North Carolina School of Medicine, Chapel Hill, North Carolina 27599-7368, U. S. A.**

The expenses associated with the review of manuscripts submitted to *Molecular Pharmacology* and other ASPET-sponsored journals that are devoted to publishing original research articles have escalated dramatically in recent years because of ever-increasing costs of postage, supplies, and other office expenses, and the growing number of manuscripts submitted for publication. Thus, it has become necessary for ASPET to follow the example of several other scientific societies which have instituted uniform manuscript handling fees. *Therefore, all manuscripts must be accompanied either by a check for $40 (in U. S. funds drawn on a U. S. bank payable to ASPET) or by a validated purchase order from the authors' institution.* The review process for submitted manuscripts will be delayed until the manuscript handling fee or purchase order is received in the Editor's office. If submission of the manuscript handling fee entails a personal financial hardship to the author(s), the fee will be waived. In that event, the author(s) should submit a request for waiver of the fee when the manuscript is submitted.

Manuscripts should be typewritten double-spaced with ample margins on one side of the paper, 8½ × 11 inches (ca. 215 × 280 mm). Submit four complete copies of the manuscript and four copies of each figure, plus one original drawing or photograph of each figure. Each half-tone figure requires four original drawings or photographs. All pages should be numbered consecutively beginning with the title page. Limit your reference listings to the minimal number required to document the manuscript adequately. In most instances 30 references or fewer should suffice.

Under usual circumstances reviewers will be instructed to return only their comments to the editorial office and to destroy manuscripts after a final decision on their acceptability has been made. Original drawings and single copies of manuscripts not accepted for publication will be returned to the authors upon request.

It is understood that the manuscripts and the results they contain will not have been published previously and are not being submitted elsewhere. If the submitted manuscript utilizes or makes bibliographic reference to articles in press, copies should be included with the manuscript. Manuscripts are accepted for review with the understanding that all persons listed as authors have given their approval for the submission of the paper; further, that any person cited as a source of personal communications has approved such citation. Written authorization may be required at the Editor's discretion. Articles and any other material published in *Molecular Pharmacology* represent the opinions of the author(s) and should not be construed to reflect the opinions of the Editor(s) and the Publisher. If and when a manuscript is published, it will become the sole property of the Journal.

Authors submitting a manuscript do so on the understanding that if it is accepted for publication, copyright in the article, including the right to reproduce the article in all forms and media, shall be assigned exclusively to the Society for Pharmacology and Experimental Therapeutics. No reasonable request by the author for permission to reproduce any of his or her contributions to the journal will be refused.

Authors are encouraged to submit electronic diskettes of the final version of their manuscripts along with the typed REVISED manuscript. Diskettes produced on IBM or IBM-compatible computers are preferred, but those produced on most Apple/MacIntosh or Wang computers can also be converted. The following word processing programs are preferred: XyWrite III Plus, Word Perfect 4.2, 5.0, or 5.1 (IBM or Macintosh), Microsoft Word (IBM or Macin-

tosh), Wang OIS (WPS), and Wordstar (IBM). Among other word processing systems that we can convert are CPT 8000, MacWrite 2.2 or 4.5, Display Write 3 or 4, Multimate, PC Write, Volkswriter, and Write Now. Authors preparing diskettes on MacIntosh computers should not use the Fast Save option. Files in ASCII can also be used, but are not preferred. Identify the diskette by providing journal name, manuscript number, senior author's name, manuscript title, name of computer file, type of hardware, operating system and version number, and software program and version number.

The journal does not assume responsibility for errors in conversion of customized software, newly released software, and special characters. Mathematics and tabular material will be processed in the traditional manner.

Accelerated Communications. In order to provide a mechanism for rapid publication of novel experimental findings of unusual and timely significance, manuscripts will be accepted for consideration as Accelerated Communications. Accelerated Communications are not intended for publication of preliminary results. Manuscripts submitted under this category should present novel results that are clearly documented and should make a conceptual advance in their field. They will be reviewed by the same criteria applied to regular papers in *Molecular Pharmacology*. The manuscript should be accompanied by a transmittal letter briefly outlining the significance of the work and providing a list of at least three scientists who would be appropriate reviewers.

Accelerated Communications will be reviewed as rapidly as possible with the aim of reaching an editorial decision within four weeks of receipt of the manuscript. It is expected that Accelerated Communications which are accepted will be published in essentially the form submitted. Manuscripts accepted without revision will be published within four to five months of initial receipt. Manuscripts accepted with a requirement for minor revisions will be published two or three months following receipt of a suitably revised version.

All manuscripts that require major revisions or that do not fit the criteria for Accelerated Communications will be returned to authors for revision and further consideration as a regular paper. Such manuscripts will retain the original submission date if revised versions are received in a timely manner.

Accelerated Communications may be submitted in the same style as regular manuscripts. Results and Discussion may be combined at the discretion of the authors. Manuscripts must not exceed five printed pages in the journal. This corresponds approximately to 25 double-spaced typewritten pages (1-inch margins) including all components of the manuscript and counting each figure as a page of typewritten text. Manuscripts that are judged to be too long will be considered as regular papers.

Organization and style of manuscripts. The policy of the Journal is to allow authors maximum freedom in organizing and presenting their material, and in expressing their ideas, provided only that clarity and conciseness are achieved. For most manuscripts, the most suitable format is: (1) Summary, (2) Introduction, (3) Materials and Methods, (4) Results, and (5) Discussion.

Certain conventions must be observed. Chemical and mathematical formulas and abbreviations should follow the *Instructions to Authors of the Journal of Biological Chemistry* (Vol. 261, pp. 1–11, January 10, 1986). Drugs must be referred to by their generic or chemical names throughout the text, but may be identified by trade name in parentheses or a footnote. The systematic name and number given by the Commission on Enzymes of the International Union of Biochemistry should be included for each enzyme of importance in a paper, at the point in the Summary or Introduction where the enzyme is first mentioned. The use of abbreviations should be minimized and abbreviations avoided in the Summary. All essential abbreviations should be defined in a single footnote when first introduced. Abbreviations of journal names should conform to the style of *Biological Abstracts*. References to papers that have been accepted for publication, but have not appeared, should be cited like other references with the abbreviated name of the journal followed by the words "in press." Copies of such papers should be sent whenever the findings described in them have a direct bearing on the paper being submitted for publication. "Personal Communications" and "Unpublished Observations" should be cited in footnotes to the text and should not be included in the reference list.

A manuscript should include the following, in the order listed: (1) Title. Numbered footnotes to the title should be avoided; acknowledgment of financial support should be given in an unnumbered footnote to the title. (2) Names of authors, their laboratory and institution. (3) A running title, not exceeding 60 characters and spaces. (4) Summary. (5) Text. Footnotes should be referred to by superscript numbers and references by numbers in parentheses. (6) References, numbered according to order of citation in the text, including title and complete pagination. Examples: 1. Goren, J. H., L. G. Bauce, and W. Vale. Forces and structural limitations of binding of thyrotropin-releasing receptor: the pyroglutamic acid moiety. *Mol. Pharmacol.* **13**:606–614 (1977). 2. Chernow, B., and J. T. O'Brian. Overview of catecholamines in selected endocrine systems, in *Norepinephrine* (M. G. Ziegler and C. R. Lake, eds.). Williams and Wilkins, Baltimore, 439–449 (1984). 3. Snedecor, G. W., and W. G. Cochran. *Statistical Methods.* Iowa State University Press, Ames (1967). (7). Footnotes, numbered according to order of appearance in the text. (8) Tables. (9) Figures. (10) Legends to figures. (11) Name and address of person to receive galley proof.

Tables. These should be numbered with arabic numerals and designed to fit the single-column width of the full-page width. Every table should have an explanatory title and sufficient experimental detail in a paragraph following the title to be intelligible without references to the text (unless the procedure is given in the Methods section, or under another table or figure). Footnotes to tables should appear beneath the tables themselves and should be designated by lower-case italic superscript letters, *a*, *b*, *c*, etc.

Figures. These should be numbered with arabic numerals. Each of the four manuscript copies should contain all of the figures. Only the original set need be of quality suitable for reproduction except in the case of half-tones, which require four sets of photographs or original drawings. These should be unmounted glossy photographs (or original India-ink drawings). Usually figures will be reduced to one column width (85 mm) and all numbers *after* such reduction should be at least 1.5 mm high. The figures must be ready, in all respects, for direct reproduction: no lettering or other art work will be done by the publisher. If symbols are not explained on the face of the figure, only standard characters, of which the printer has type, may be used (×, ○, ●, □, ■, △, ▲, ◐). The back of each photograph should bear its number, and the legend TOP at the appropriate edge. The list of legends for the figures should give captions and sufficient experimental detail, as required for tables.

Page proof. Authors will be billed for substantial changes in page proof. The Editors are very much interested in having accepted contributions appear in the earliest possible issue of the Journal, and therefore request that galley proof be returned within 24 hours after its receipt. In exceptional cases, a "Note added in proof" may be attached and will be published if the Editor approves.

Reprints and page charges. An order form for reprints as well as information on the estimation of page charges will be mailed with galley proof. Please direct questions on reprints, page charges, or other business matters to Kay Croker, Executive Officer, American Society for Pharmacology and Experimental Therapeutics, 9650 Rockville Pike, Bethesda, Md. 20814. Telephone (301)530-7060.

Your Window on the World of Medicine



THE LANCET

Vol 338 LONDON AND BALTIMORE SATURDAY 7 SEPTEMBER 1991 No 8767

ORIGINAL ARTICLES
Placebo-controlled, double-blind, cross-over trial of growth hormone treatment in prepubertal children with chronic renal failure 585
A. C. S. Hokken-Koelega, T. Stijnen, S. M. P. F. de Muinck Keizer-Schrama, J. M. Wit, E. D. Wolff, M. C. J. W. de Jong, R. A. Donckerwolcke, N. C. B. Alsbad, A. Bot, W. F. Blum, S. L. S. Drop 590
Proinflammatory cytokines in acute asthma
P. H. Brown, G. K. Crompton, A. P. Greening 593
Clinical and electrophysiological aspects of acute paralytic disease of children and young adults in northern China
G. M. McKhann, D. R. Cornblath, T. Ha, C. Y. Li, A. Y. Bai, H. S. Wu, Q. F. Yu, W. C. Zhang, Z. Zhaori, Z. Jiang, J. W. Griffin, A. K. Asbury 597
Heparin treatment in sinus venous thrombosis
K. M. Einhäupl, Arno Villringer, Wolfgang Meister, Susan Mehraein, Christoph Garner, Max Pellkofer, R. L. Haberl, Hans-Walter Pfister, Peter Schmiedek

SHORT REPORT
GM-CSF instead of autologous bone-marrow transplantation after the BEAM regimen 601
J. Ph. Laporte, L. Fouillard, L. Douay, I. Eugene-Jolchine, P. Isnard, J. Soubeyrat, A. Najman, N. C. Gorin

EDITORIALS
Transesophagitis 603
Solving the weanling's dilemma: power-flour to fuel the gruel? 604
Rectal prolapse 605
Monitoring TURP 606

REVIEW ARTICLE
Slowing the spread of human immunodeficiency virus in developing countries 608
Malcolm Potts, Roy Anderson, Marie-Claude Boily

SCREENING
Pilot study of screening for prostate cancer in general practice 613
D. J. Chadwick, Terry Kemple, J. P. Astley, A. G. MacIver, D. A. Gillatt, Paul Abrams, J. C. Gingell

CLINICAL PRACTICE
Change in obstetric practice in response to fear of litigation in the British Isles 616
M. Benn, A. Clark, J. G. Grudzinskas

VIEWPOINT
Setting the record straight on low-dose heparin 619
A. G. Shulman

BOOKSHELF
Medical Management of Breast Cancer 620
The Psychoses of Epilepsy 620
Basic Behaviour Therapy 621
Post-viral Fatigue Syndrome 621

NEWS and COMMENT
London Perspective
Taking the temperature of the NHS 622
Round the World
Australia: Evaluation of prescription drugs 623
Russian Republic: Perfidious or professional? 624
Germany: Horror hospital 624
Sudan: Kala-azar should be in the news 624
Medicine and the Law
Group litigation on the horizon 625
Noticeboard 626
Unplanned pregnancies 626
Medical research in Europe 626
Soviet psychiatry 627
Lighten the load 627
Tumble die 627
Don't be CAGEy 628
Food blockade for malaria parasite 628
Global policy on AIDS 628
Blood donor screening for hepatitis C 628
In England Now 628
International Diary 628
LETTERS to the EDITOR 629-644

NEWSPAPER

There's a world outside your office window. Beyond the hospital corridor. A world that shapes and influences the way you practice medicine. And *The Lancet* delivers this world to your door every week.

THE LANCET

Timely
Innovative
Independent
Provocative
Relevant

To order, call
TOLL FREE
in the U.S. or Canada:
1-800-638-6423
Or clip and mail this coupon.

GUARANTEE
If *The Lancet* ever stops meeting your needs, simply tell us to "cancel." We'll end your subscription immediately, and send you a prompt refund for all unmailed copies.

YES, start my subscription to *The Lancet!*

☐ 3 yrs ☐ 2 yrs ☐ 1 yr
☐ Personal $95/yr
☐ Institutional $130/yr
☐ Resident/Fellow* $53/yr
☐ Medical student* $45/yr

Canadian subscribers, add $20/yr. for postage. Canadian subscribers must add 7% GST. Maryland residents add 5% sales tax. California residents, add 8% sales tax. Rates valid through October 31, 1992, and applicable for U.S. and Canadian subscribers only.

*Please specify your institution and training status

Payment options:
☐ Check enclosed (payable to Williams & Wilkins)
☐ American Express ☐ VISA
☐ MasterCard ☐ Bill me

Return coupon to:
Williams & Wilkins
P.O. Box 23291
Baltimore, MD 21203-9990

Card # Exp. date
Signature
Name
Address
City/State/Zip

LANCET 53504 J2099S04

Previous Editors

1965 Avram Goldstein, *Editor*. Stanford University.

1968 Paul Talalay, *Editor*; Donald S. Coffey, *Associate Editor*. Johns Hopkins University.

1971 Steven E. Mayer, *Editor*, Palmer W. Taylor, *Associate Editor*. University of California at San Diego.

1975 George I. Drummond, *Editor*; H. Joseph Goren, *Associate Editor*. University of Calgary.

1978 Norman Kirschner, *Editor*; Theodore A. Slotkin, *Associate Editor*. Duke University.

1983 Joel G. Hardman, *Editor*; Lee Limbird, F. Peter Guengerich, *Associate Editors*. Vanderbilt University.

1986 William A. Catterall, *Editor*; Joseph A. Beavo, Mont R. Juchau, Neil M. Nathanson, Daniel R. Storm, Frank F. Vincenzi, *Associate Editors*. University of Washington, Seattle.

INFORMATION TO SUBSCRIBERS

MOLECULAR PHARMACOLOGY is published monthly, two volumes a year, beginning in January & July. Instructions to Authors will be found in every issue.

Correspondence concerning business matters should be addressed to Williams & Wilkins, 428 East Preston St., Baltimore, Maryland 21202-3993 U.S.A.

Correspondence regarding editorial matters should be addressed to the Editor, Dr. T. Kendall Harden, CB 7368, Department of Pharmacology, University of North Carolina School of Medicine, Chapel Hill, NC 27599-7368.

Annual Subscription Rates—U. S. A. AND POSSESSIONS: personal, $100.00; institutional, $210.00, single copy, $18.00. FOREIGN: personal, $130.00; institutional, $240.00; single copy, $21.00. (Prices subject to change.) Institutional (multiple reader) rate applies to libraries, schools, hospitals, clinics, group practices, and federal, commercial, and private institutions and organizations. Foreign subscribers who wish to have issues sent by air mail may inquire of the publisher for the additional cost. The GST Tax Number for Canadian subscribers is 123394371.

Change of address: Publisher must be notified 60 days in advance. Journals undeliverable because of incorrect address will be destroyed. Duplicates can be obtained (if available) from the publisher at the regular price of single issues.

New subscriptions are entered to begin with the next issue to publish unless instructed otherwise by the subscriber. Subscriptions run for a 12-month period.

To avoid a break in your series, subscriptions should be renewed promptly. The publisher cannot guarantee to supply back issues on belated renewals.

Reprints of individual articles are available *only* from authors.

Microfilm. For availability, inquire of Williams & Wilkins.

Williams & Wilkins, Baltimore, MD 21202-3993 U. S. A.